Screener
Nautilus Biotechnology, Inc. NAUT Q3 2026 earnings
Reported October 27, 2026 · Before market open
Revenue$234.0KBeat by $27.8K
EPS-$0.12Beat by $0.02
Revenue estimate$206.3K
EPS estimate-$0.14
“The third quarter marked an important step in demonstrating the power and scalability of Iterative Mapping on our Voyager platform. Our seminal publication in Nature Methods highlights the unique biological insights that our technology can deliver. In addition, our proteoform expansion initiative is on-track, with early oncology assay results that demonstrate the performance we established with Tau is repeatable across additional targets. This repeatability is fundamental to our strategy of building a broad portfolio of proteoform assays, and the progress we are seeing reinforces our confidence in our technology, our development roadmap, and our planned instrument availability in the middle of 2027.”
Next report
Date not yet announcedVersus estimates
Revenue
Q3 2026$234.0KBeat by $27.8K
Q2 2026$190.0KBeat by $90.0KDiluted EPS
FAQ
- When did Nautilus Biotechnology, Inc. report Q3 2026 earnings?
- Nautilus Biotechnology, Inc. (NAUT) reported Q3 2026 earnings on October 27, 2026 before market open.
- What were Nautilus Biotechnology, Inc.'s Q3 2026 revenue and EPS?
- Nautilus Biotechnology, Inc. reported revenue of $234.0K and eps of $-0.12 for Q3 2026.
- Did Nautilus Biotechnology, Inc. beat estimates in Q3 2026?
- Revenue beat the consensus estimate of $206.3K by $27.8K. EPS beat the consensus estimate of $-0.14 by $0.02.
- How did Nautilus Biotechnology, Inc.'s Q3 2026 results compare year-over-year?
- Compared to the same quarter a year prior, eps declined 9.1% from $-0.11.
- Where can I find Nautilus Biotechnology, Inc.'s Q3 2026 SEC filings?
- You can read the 8-K earnings release (0001808805-26-000049) and the 10-Q periodic report (0001808805-26-000052) directly on SEC EDGAR. The filing index links above go to sec.gov.
